fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.
it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done.
.
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.
.
.
the youngest claimant was aged 20, and the eldest aged 89, while the average policy duration at claim stage was 10 years.
.
.